Interactive case-study focused webinar to learn about:
• Differences in survival, CNS control and toxicity profiles among current and
emerging treatment specifically in the landscape of 1L ALK+ NSCLC
• The clinical utility of targeted next generation sequencing (NGS) in devising a
personalized treatment plan for ALK+ patients be it for initial therapy or subsequent
lines upon development of acquired resistance
• Experts sharing on their treatment algorithm for sequencing ALK inhibitors and
panel discussion on YOUR topic of choice. This event will be dynamic and
interactive using live survey and audience questions.